Everest Medicines Files Velsipity for Ulcerative Colitis in China
Everest Medicines (HKG: 1952) announced it has submitted a marketing filing in China for Velsipity...
Bristol-Myers Squibb Growth Portfolio Drives 17% Revenue Increase in 2025
Bristol-Myers Squibb (BMS, NYSE: BMY) reported fourth‑quarter 2025 revenue of USD 12.5 billion, up 1% year‑on‑year (YOY), while...
Keytruda Wins 20th China Approval for Endometrial Cancer in First-Line Setting
Merck & Co. (MSD, NYSE: MRK) announced that Keytruda (pembrolizumab) has received its 20th indication approval...
Give Kids a Chance Act Extends FDA Pediatric Research Authority and PRV Program
The US Congress has introduced the Give Kids a Chance Act, legislation aimed at broadening...
Eli Lilly Revenue Surges 45% to $65.2B on Incretin Portfolio Strength
Eli Lilly and Company (NYSE: LLY) reported fourth‑quarter 2025 revenue of USD 19.29 billion, up 43% year‑on‑year (YOY),...
Novartis Revenue Growth Hits 8% Despite Entresto and Promacta Generic Erosion
Novartis AG (NYSE: NVS) reported full‑year 2025 net sales of USD 54.5 billion, up 8% year‑on‑year (YOY) at...
Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal
Everest Medicines Limited (HKG: 1952) announced a licensing agreement with Micot, a polypeptide NME drug...
GE HealthCare Revenue Grows 5% to $20.6B on Imaging and Diagnostics Strength
GE HealthCare (NASDAQ: GEHC) reported fourth‑quarter 2025 revenue of USD 5.7 billion, up 7.1% year‑on‑year (YOY), bringing full‑year...
MediTrust Mabwell Insurance Ecosystem Partnership
Shanghai MediTrust Health Technology Group Co., Ltd. (a subsidiary of Shanghai Pharmaceuticals) announced a comprehensive...
Hanx Biopharma HX111 ADC Begins Phase I Trial for Lymphoma and Solid Tumors
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HKG: 3378) announced the initiation of a Phase I clinical...
Pfizer Launches Migraine Management Zone at China Pharmacy
Pfizer Inc. (NYSE: PFE) in collaboration with GuoDa Drugstore Co., Ltd. (part of Sinopharm) this week...
Shouyao’s SY-9453 MAT2A Inhibitor Gets NMPA Nod for MTAP-Deleted Tumors
Shouyao Holdings (Beijing) Co., Ltd. (SHA: 688197) announced that the National Medical Products Administration (NMPA)...
Innovent Biologics Revenue Surges 45% on Oncology Portfolio Expansion
Innovent Biologics, Inc. (HKG: 1801) reported strong financial results for Q4 and full‑year 2025, with total...
Huadong Medicine DR10624 Gets NMPA Nod for Hypertriglyceridemia Study
Huadong Medicine Co., Ltd (SHE: 000963) announced that its subsidiary Doer Biologics has received National...
Takeda Ends $128M Kyoto University iPSC Project After Decade of Research
Takeda Pharmaceutical (TYO: 4502, NYSE: TAK) announced the termination of its ten‑year induced pluripotent stem cell (iPSC)...
Beijing Online Consultation Pilot Gets NHC Approval for Children’s Care
China’s National Health Commission (NHC) has approved the “Standardized Pilot Program for Online Initial Consultations...
AstraZeneca Saphnelo Faces FDA Setback with Complete Response Letter
AstraZeneca (AZ, NASDAQ: AZN) announced it has received a Complete Response Letter (CRL) from the U.S....
AbbVie Immunology Portfolio Drives $61.2B Revenue in 2025
AbbVie Inc. (NYSE: ABBV) reported fourth‑quarter revenue of USD 16.618 billion, up 9.5% year‑on‑year (YOY), bringing full‑year 2025...
Mirxes Partners with XtalPi and Signet on AI-Driven Gastric Cancer System
Mirxes Singapore (HKG: 2629) announced a partnership with XtalPi Inc. (QuantumPharm, HKG: 2228) and its...
Lishan Biopharma Licenses Evogene’s LS-LBP-002 for Global Oncology Development
Shanghai Lishan Biopharmaceuticals Co., Ltd. announced a licensing agreement with Israel‑based Evogene Ltd. (NASDAQ: EVGN) for...